Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
The Journal of Heart Valve Disease|February 16, 2013
Intra-atrial placement of a mitral prosthesis in patients with severe mitral annular calcificationChristos G Mihos, Orlando Santana, Julio Peguero, et al.
Cancers|June 20, 2019
A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular CarcinomaDevalingam Mahalingam, Julio Peguero, Putao Cen, et al.
JTO Clinical and Research Reports|October 15, 2024
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 StudyMatthew G Krebs, Martin Forster, Margarita Majem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2024
Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell CarcinomaMartin Forster, Irene Brana, Antonio L Pousa, et al.
The Oncologist|June 2, 2020
Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III TrialLee S Schwartzberg, Gajanan Bhat, Julio Peguero, et al.
Journal for Immunotherapy of Cancer|October 26, 2019
Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trialUlka Vaishampayan, Patrick Schöffski, Alain Ravaud, et al.
International Journal of Surgery Case Reports|October 1, 2018
The impact of a rapid imaging protocol in acute cholecystitis-prospective cohort studyLimael E Rodriguez, Jorge A Sanchez-Vivaldi, Miguel P Velez-Quiñones, et al.
Oncotarget|May 17, 2018
Signature program: a platform of basket trialsEric D Slosberg, Barinder P Kang, Julio Peguero, et al.
The Oncologist|December 26, 2022
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint InhibitorsFabrice Barlesi, Nicolas Isambert, Enriqueta Felip, et al.
JCO Precision Oncology|February 1, 2022
Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket StudyJulio Peguero, Davendra P S Sohal, Bert H O'Neil, et al.
Pageof 2